Omecamtiv Mecarbil (OM)

Phase 3

Cytokinetics, Incorporated (CYTK)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Sep '27

CYTKPhase 3$9.1B

Omecamtiv Mecarbil (OM) Phase 3 Est. Readout (COMET-HF)

Omecamtiv Mecarbil (OM)• Heart Failure1,800

Sep 2027~Estimated

CT.gov

00%

Competitive Landscape

6 competitors in Heart Failure

CYADInjection of C3BS-CQR-1

Phase 3

CYADC3BS-CQR-1

Phase 3

JNJJNJ-39588146 5 ng/kg/min

Phase 2

NVOCDR132L

Phase 2

HSCSWNebulized Sodium Nitrite

Phase 2

View Full Landscape

Drug Information

Target Indication

Heart Failure

Clinical Trial

NCT06736574

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

CYTK

Cytokinetics, Incorporated

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

tirasemtivPhase 3

Amyotrophic Lateral Sclerosis (ALS)

AficamtenPhase 3

Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

Omecamtiv MecarbilPhase 3

Heart Failure With Reduced Ejection Fraction

Aficamten (CK-3773274)Phase 3

Obstructive Hypertrophic Cardiomyopathy (oHCM)

Omecamtiv Mecarbil Matrix F1 FormulationPhase 2

Modified Release Oral Formulation

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts